Zimmer Biomet Holdings Inc (ZBH) Receives $129.95 Average PT from Brokerages

Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given a consensus recommendation of “Hold” by the twenty-six research firms that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $129.95.

Several equities research analysts have recently issued reports on ZBH shares. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Friday, April 26th. Cantor Fitzgerald set a $135.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a research note on Friday, April 26th. SunTrust Banks raised their price target on shares of Zimmer Biomet to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Saturday, February 2nd. Finally, Evercore ISI upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price objective for the company in a research note on Monday, April 8th.

Shares of ZBH stock opened at $114.52 on Monday. The company has a quick ratio of 0.97, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. Zimmer Biomet has a 12-month low of $96.99 and a 12-month high of $134.55. The company has a market cap of $23.45 billion, a PE ratio of 14.99, a P/E/G ratio of 2.14 and a beta of 1.19.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.86 by $0.01. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. The company had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the business posted $1.91 EPS. Zimmer Biomet’s quarterly revenue was down 2.1% compared to the same quarter last year. Equities analysts forecast that Zimmer Biomet will post 7.81 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date was Thursday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.84%. Zimmer Biomet’s dividend payout ratio is 12.57%.

In other news, Director Syed A. Jafry purchased 1,925 shares of Zimmer Biomet stock in a transaction dated Friday, March 1st. The stock was purchased at an average cost of $125.52 per share, for a total transaction of $241,626.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.72% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Zimmer Biomet by 3.2% during the 1st quarter. BlackRock Inc. now owns 16,474,877 shares of the medical equipment provider’s stock valued at $2,103,841,000 after purchasing an additional 509,160 shares in the last quarter. Vanguard Group Inc grew its position in shares of Zimmer Biomet by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 14,511,433 shares of the medical equipment provider’s stock valued at $1,907,818,000 after purchasing an additional 228,894 shares in the last quarter. American Century Companies Inc. grew its position in shares of Zimmer Biomet by 23.1% during the 4th quarter. American Century Companies Inc. now owns 5,425,619 shares of the medical equipment provider’s stock valued at $562,745,000 after purchasing an additional 1,016,489 shares in the last quarter. Northern Trust Corp grew its position in shares of Zimmer Biomet by 1.7% during the 4th quarter. Northern Trust Corp now owns 3,590,559 shares of the medical equipment provider’s stock valued at $372,414,000 after purchasing an additional 61,577 shares in the last quarter. Finally, OppenheimerFunds Inc. grew its position in shares of Zimmer Biomet by 7.9% during the 1st quarter. OppenheimerFunds Inc. now owns 3,156,333 shares of the medical equipment provider’s stock valued at $403,063,000 after purchasing an additional 231,307 shares in the last quarter. Hedge funds and other institutional investors own 88.49% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: Trading Ex-Dividend

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.